drugset
drugset / Trial / NCT02279953

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

NCT02279953 ↗

Phase 3 Completed 151 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).

Timeline

Start
2014-10
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 20 mg Oral
Background Citalopram Small molecule — Oral
Background Escitalopram Small molecule — Oral
Background Sertraline Small molecule — Oral

Indications

major depressive disorder